A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant.
about
Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy.Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience.Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations.Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood TransplantationGVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT.
P2860
Q33413498-1C175713-95AB-4E93-A1CB-36F43E23C126Q33424153-10771BD3-73F0-4AAF-863B-D7102E61940CQ33424311-5B7D5C89-B45C-4FEB-9CB7-0035A56B3242Q34272554-99070FBF-E682-44EA-985C-A4E3726CE3B7Q35231363-38B8FF37-75E6-4914-9ACA-F3AF1ADE89BEQ36474050-B35CA1DF-B309-456E-AAB7-EB2ABF03F572Q36777485-6C7BDEDD-A508-495A-9FA3-5115CC14B761Q36892442-84C36761-9842-4CDF-9ECB-EF59AFC6D240Q38202155-0A62ACA8-EEF6-4EA4-A00A-6F5B4FB90CBBQ38773356-D0934F24-26C0-421F-A7ED-21B2A334AC95Q40486613-23F82A84-7D72-4E05-B03F-8571EC531788Q40577820-E0094705-5758-42FD-978E-C84658129271Q48261069-E56C42DE-8309-4CA6-A739-FC57AA56D414
P2860
A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A phase II study of sirolimus, ...... related-donor PBSC transplant.
@ast
A phase II study of sirolimus, ...... related-donor PBSC transplant.
@en
type
label
A phase II study of sirolimus, ...... related-donor PBSC transplant.
@ast
A phase II study of sirolimus, ...... related-donor PBSC transplant.
@en
prefLabel
A phase II study of sirolimus, ...... related-donor PBSC transplant.
@ast
A phase II study of sirolimus, ...... related-donor PBSC transplant.
@en
P2093
P2860
P356
P1476
A phase II study of sirolimus, ...... related-donor PBSC transplant.
@en
P2093
A Nademanee
D S Snyder
D Senitzer
P M Parker
R Nakamura
P2860
P2888
P304
P356
10.1038/BMT.2012.175
P407
P577
2012-09-24T00:00:00Z